Swiss CDMO Carbogen AMCIS Expands ADC Production Capabilities with $31M Investment
In a significant move to meet the growing demand for antibody-drug conjugates (ADCs), Swiss contract development and manufacturing organization (CDMO) Carbogen AMCIS has announced a substantial investment to enhance its production capabilities. The company, along with an unnamed Japanese partner, will invest 25.5 million Swiss francs ($31 million) to upgrade two of its domestic facilities for the commercial production of ADC linkers.
Expansion Plans and Timeline
Carbogen AMCIS plans to outfit its facilities in Aarau and Neuland for ADC production, with completion dates set for the first and third quarters of 2027, respectively. The upgrades will include the installation of 850-liter reactors and agitated filter dryers at both sites.
Carl Baker, Carbogen's drug substance business unit vice president, emphasized the strategic importance of this investment, stating, "By investing in both Aarau and Neuland, we're ensuring that our infrastructure keeps pace with our customers' ambitions."
This latest investment builds upon Carbogen's previous efforts to bolster its ADC capabilities. Four years ago, the company upgraded its API site at its headquarters in Bubendorf, Switzerland, to manufacture ADC linkers.
Industry-wide ADC Manufacturing Expansion
Carbogen's expansion is part of a broader trend in the pharmaceutical industry, with several companies investing heavily in ADC production capabilities:
-
Lonza, another Swiss CDMO, recently announced plans to double its ADC production capacity at its Visp, Switzerland site. The expansion includes the addition of two manufacturing suites and the creation of 200 new jobs.
-
AstraZeneca and Daiichi Sankyo, partners on the ADC drug Enhertu, have each announced significant investments in ADC manufacturing facilities. AstraZeneca plans to invest $1.5 billion in a new facility in Singapore, while Daiichi Sankyo will invest $1 billion in a new site in Germany.
These investments reflect the pharmaceutical industry's growing focus on ADCs as promising targeted cancer treatments. As demand for these complex therapies continues to rise, CDMOs and drugmakers are racing to expand their production capabilities to meet market needs.
References
- Swiss CDMO Carbogen bolsters ADC production capability with $31M investment
Swiss CDMO Carbogen AMCIS, an active pharmaceutical ingredient manufacturer, revealed that it and an unnamed Japanese partner will invest 25.5 million Swiss francs ($31 million) to outfit two of Carbogen’s three domestic API facilities for production of ingredients used to make commercial antibody-drug conjugates.
Explore Further
What are the expected market trends and demand forecasts for ADCs over the next few years?
Who are the major competitors in the ADC manufacturing sector, and what are their recent investment activities?
What technologies or innovations are being implemented in the upgrades at Carbogen AMCIS's Aarau and Neuland facilities?
How do the recent expansions by companies like Lonza, AstraZeneca, and Daiichi Sankyo impact the global ADC supply chain?
What is the strategic importance of the unnamed Japanese partner in Carbogen AMCIS's investment plan?